Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will be hosting a webinar to provide an overview of how LINZESS will be reflected in Ironwood’s quarterly income statements following its commercial availability in the U.S. Ironwood will co-commercialize the product in the U.S. through its collaboration with Forest Laboratories, Inc.
The webinar will take place on Tuesday, November 6, 2012 at 12:00 p.m. Eastern Time. Individuals interested in participating in the webinar should visit the Investors section of Ironwood’s website at www.ironwoodpharma.com; please log on at least 15 minutes prior to the start of the event to ensure adequate time for any software downloads that may be required. For listen-only participation, the webinar can also be accessed by dialing (866) 437-1772 (U.S. and Canada) or (973) 638-3229 (international) and use the conference ID number 45259150.
A replay of the webinar will be available on Ironwood’s website or via telephone starting November 6, 2012 at approximately 3:00 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on November 13, 2012. To listen to the replay by phone, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) and use conference ID number 45259150.
About Ironwood PharmaceuticalsIronwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts